Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Noninvasive Therapy for Tinnitus

NCT: NCT07071480 · RECRUITING

NCT IDNCT07071480
StatusRECRUITING
Start Date2025-11-24
Completion2027-05-31
SponsorRestorear Devices LLC (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this interventional clinical study is to establish mild therapeutic hypothermia, delivered non-invasively to the structures of the inner ear, as a safe and repeatable therapeutic method for symptomatic relief of tinnitus. The study will assess both objective and subjective measures to address two main aims: 1. Ascertain the benefits of mild therapeutic hypothermia for symptomatic relief of chronic tinnitus in participants using the ReBound hypothermia device. 2. Ascertain the benefits of mild therapeutic hypothermia for symptom management in chronic tinnitus participants over six months using the ReBound device. Participants will wear the ReBound hypothermia device for 30 minutes in a single session. Researchers will compare results from those receiving the therapy to those from a control group (sham therapy). Participants will also use the device in-home for 6 months and monitor their symptoms with online surveys.

Frequently Asked Questions

What is Noninvasive Therapy for Tinnitus?

Noninvasive Therapy for Tinnitus is a clinical trial registered under NCT07071480. Current status: RECRUITING.

What is the status of NCT07071480?

The current status of NCT07071480 (Noninvasive Therapy for Tinnitus) is: RECRUITING.

When did Noninvasive Therapy for Tinnitus start?

Noninvasive Therapy for Tinnitus started on 2025-11-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.